Update on novel antiepileptic drugs

Bibliography

• SANDER JW, SHORVON SD: Incidence and prevalence studies in epilepsy and their methodo-logical problems: a review. J. Neurol. Neurosurg. Psychiatry (1987) 50:829–839.
   PubMed Web of Science ®Google Scholar
• A comprehensive review of the epidemiology of epilepsy worldwide with a special emphasis on methodological problems that can result in spurious results.
   Google Scholar
• COCKERELL OC, HART YM, SANDER JVVAS, SHORVON SD: The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. (1994)18:249–260.
   PubMed Web of Science ®Google Scholar
• A thorough estimation of the cost of epilepsy, both in terms of direct and indirect costs.
   Google Scholar
• SANDER JW: Some aspects of prognosis in the epilepsies: a review. Epilepsia (1993) 34:1007–1016.
   PubMed Web of Science ®Google Scholar
• An excellent review of all aspects of the prognosis of epilepsy.
   Google Scholar
• WALKER MC, SANDER JVVAS: The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology (1996) 46:912–914.
   PubMed Web of Science ®Google Scholar
• A controversial review considering the outcome measures that should be used in antiepileptic drug trials, and the relatively disappointing impact of new antiepileptic drugs on the prognosis of epilepsy.
   Google Scholar
• MATTSON RH, CRAMER JA, COLLINS JF, et al.: Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalised tonic-clonic seizures. New Engl. J. Med. (1985) 313:145–151.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JWAS: Overtreatment with antiepileptic drugs: how extensive is the problem CNS Drugs (1994) 2(5):335–340.
   Web of Science ®Google Scholar
• PATSALOS PN, SANDER JVVAS: Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Safety (1994) 11:37-67. A thorough review of new antiepileptic drugs.
   PubMedGoogle Scholar
• WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther. (1995) 67:351–384.
   PubMed Web of Science ®Google Scholar
• A thorough review of new antiepileptic drug pharmacokinetics with a proposed scoring system which emphasises those aspects of the pharmacokinetics which are clinically important.
   Google Scholar
• LOSCHER W, SCHMIDT D: New drugs for the treatment of epilepsy. Curr. Opin. Invest. Drugs (1993) 2(10):1067–1095.
   Google Scholar
• An excellent review of antiepileptic drug development, including animal models and mechanisms of action.
   Google Scholar
• PENNELL PB, OGAILY MS, MACDONALD RL: Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology (1995) 45:456–460.
   PubMed Web of Science ®Google Scholar
• O'NEIL MG, PERDUN CS, WILSON MB, MCGOWN ST, PATEL S: Felbamate-associated fatal acute hepatic necrosis. Neurology (1996) 46:1457–1459.
   PubMed Web of Science ®Google Scholar
• Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York (1995):823–827.
   Google Scholar
• WALLIS RA, PANIZZON KL: Felbamate neuroprotection against CA1 traumatic neuronal injury. Eur. I Pharmacol. (1995) 294:475–482.
   PubMed Web of Science ®Google Scholar
• CHRONOPOULOS A, STAFSTROM C, THURBER S, et al.: Neuroprotective effect of felbamate after kainic acid-induced status epilepticus. Epilepsia (1993) 34:359–366.
   PubMed Web of Science ®Google Scholar
• WASTERLAIN CG, ADAMS LM, SCHWARTZ PH, et al.: Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia-ischemia. Neurology (1993) 43:2303–2310.
   PubMed Web of Science ®Google Scholar
• WILDER BJ, CAMPBELL K, RAMSAY RE, et al.: Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch. Neurol. (1996) 53:764–768.
   PubMed Web of Science ®Google Scholar
• JAMERSON BD, DUKES GE, BROUVVER KL, et al.: Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy (1994) 14:47–52.
   PubMed Web of Science ®Google Scholar
• RAMSAY RE, DETOLEDO J: Intravenous administration of fosphenytoin: options for the management of seizures. Neurology (1996) 46:S17–19.
   PubMed Web of Science ®Google Scholar
• TAYLOR CP: Emerging perspectives on the mechanism of action of gabapentin. Neurology (1994) 44\(Suppl. 5):S10–16.
   PubMedGoogle Scholar
• GEE NS, BROWN JP, DISSANAYAKE VU, et al.: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. I Biol. Chem. (1996) 271:5768–5776.
   Web of Science ®Google Scholar
• TAYLOR CP, VARTANIAN MG, YUEN PW, et al.: Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. (1993) 14:11–15.
   PubMed Web of Science ®Google Scholar
• KILPATRICK ES, FORREST G, BRODIE MJ: Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia (1996) 37:534–538.
   PubMed Web of Science ®Google Scholar
• Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York (1995):1063–1070.
   Google Scholar
• WALKER MC, SANDER JVVAS: Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure (1996) 5:199–204.
   PubMed Web of Science ®Google Scholar
• RING HA, TRIMBLE MR, COSTA DC, et al.: Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. I Neurol. Neurosurg. Psychiatry (1992) 55:758–761.
   PubMed Web of Science ®Google Scholar
• AICARDI J, MUMFORD JP, DUMAS C, WOOD S: Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia (1996) 37:638–642.
   PubMed Web of Science ®Google Scholar
• PITKANEN A: Treatment with antiepileptic drugs: possible neuroprotective effects. Neurology (1996) 47:S12–16.
   PubMed Web of Science ®Google Scholar
• A paper describing the possible neuroprotective effects of antiepileptic drugs given prior to status epilepticus. This may be important as it has been suggested that seizures themselves may produce neuronal damage, and thus drugs that prevent this damage may improve the prognosis in some epilepsy syndromes.
   Google Scholar
• WALKER MC, SANDER JW: Developments in antiepileptic drug therapy. Curr. Opin. Neurol. (1994) 7:131–139.
   PubMed Web of Science ®Google Scholar
• GOWER AJ, NOYER M, VERLOES R, GOBERT J, WULFERT E: UCB L059, a novel anti-con-vulsant drug: pharmacological profile in animals. Eur. I Pharmacol. (1992) 222:193–203.
   PubMed Web of Science ®Google Scholar
• NOYER M, GILLARD M, MATAGNE A, HENICHART JP, WULFERT E: The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes. Eur. Pharmacol. (1995) 286:137–146.
   PubMed Web of Science ®Google Scholar
• STEIN U, KLESSING K, CHATTERJEE SS: Losigamone. Epilepsy Res. Suppl. (1991) 3:129–133.
   PubMedGoogle Scholar
• DIMPFEL W, CHATTERJEE SS, NOLDNER M, TICKU MK: Effects of the anticonvulsant losigamone and its isomers on the GABA-A receptor system. Epilepsia (1995) 36:983–989.
   PubMed Web of Science ®Google Scholar
• ANDERSEN KE, BRAESTRUP C, GRONVVALD FC, et al.: The synthesis of novel GABA uptake inhibitors.!. Elucidation of the structure-activity studies leading to the choice of (R)-1-14,4-bis(3-methyl-2-thieny1)-3-buteny11-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidate. J. Med. Chem. (1993) 36:1716–1725.
   PubMed Web of Science ®Google Scholar
• An interesting paper demonstrating how different synthetic approaches can lead to different drug candidates and the basis on which the final choice is made.
   Google Scholar
• WALKER MC, LI LM, SANDER JWAS: Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. Br. Med. J. (1996) 313:1184-1185. The results of this audit suggest that the newer antiepileptic drugs have no effect on the prognosis of severe refractory epilepsy.
   Google Scholar
• POP E, BODOR N: Chemical systems for delivery of antiepileptic drugs to the central nervous system. Epilepsy Res. (1992) 13:1–16.
   PubMed Web of Science ®Google Scholar
• This paper describes a method of improving antiepileptic drug penetration into the central nervous system and by this means possibly improving their efficacy.
   Google Scholar
• SVEINBJORNSDOTTIR S, SANDER JW, UPTON D, et al.: The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165-174. A study in which a drug that was well tolerated in healthy volunteers had unacceptable adverse events in patients with epilepsy.
   PubMedGoogle Scholar
• JOHNSON JW, ASCHER P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325:529–531.
   PubMed Web of Science ®Google Scholar
• DE VAREBEKE JP, NIEBES P, PAUVVELS G, ROBA J, KORF J: Effect of milacemide, a glycinamide derivative, on the rat brain gamma-aminobutyric acid system. Biochem. Pharmacol. (1983) 32:2751–2755.
   PubMed Web of Science ®Google Scholar
• SEMBA J, CURZON G, PATSALOS PN: Antiepileptic drug pharmacokinetics and neurophar-macokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br. I Pharmacol. (1993) 108:1117–1124.
   PubMed Web of Science ®Google Scholar
• An important study demonstrating how an understanding of an antiepileptic drug's neuropharmacolcinetics can explain its inefficacy in clinical trials.
   Google Scholar
• SANDER JW, PATSALOS PN: An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. (1992) 13:89–92.
   PubMed Web of Science ®Google Scholar
• DE SARRO G, CHIM1RRI A, DE SARRO A, et al.: GYM 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J Pharmacol. (1995) 294:411–422.
   PubMed Web of Science ®Google Scholar
• SHIMIZU-SASAMATA M, KAWASAKI-YATSUGI S, et al.: YlV190K: pharmacological charac-terization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kai-nate receptor antagonist. J. Pharmacol. Exp. Ther. (1996) 276:84–92.
   PubMed Web of Science ®Google Scholar
• OHMORI J, KUBOTA H, SHIMIZU-SASAMATA M, OKADA M, SAKANIOTO S: Novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-y1)-7-nitro-2,3(1H,4H)-pyrido 12,3-blpyrazinedione and related compounds. J. Med. Chem. (1996) 39:1331–1338.
   PubMed Web of Science ®Google Scholar
• DALBY NO, THOMSEN C: Modulation of seizure activity in mice by metabotropic glutamate receptor ligands. I Pharmacol. Exp. Ther. (1996) 276:516–522.
   PubMed Web of Science ®Google Scholar
• MONN JA, VALLI MJ, JOHNSON BG, et al.: Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cydase. J. Med. Chem. (1996) 39:2990–3000.
   PubMed Web of Science ®Google Scholar
• DURMULLER N, CRAGGS M, MELDRUM BS: The effect of the non-NMDA receptor antagonist GYM 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. (1994) 17:167–174.
   PubMed Web of Science ®Google Scholar
• A paper describing the different effects of specific glutamate receptor antagonists on the development of epilepsy, and seizures.
   Google Scholar
• TEMKIN NR, DIKMEN SS, WILENSKY AJ, et al.: A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. New Engl. J. Med. (1990) 323:497-502. A paper showing the inefficacy of phenytoin in preventing the development of late epilepsy following head trauma.
   PubMedGoogle Scholar
• FOY PM, CHADWICK DW, RAJGOPALAN N, JOHNSON AL, SHAW MDM: Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy I Neural. Neurosurg. Psychiatry (1992) 55:753–757.
   PubMed Web of Science ®Google Scholar
• A paper demonstrating the inefficacy of both carbamazepine and phenytoin as prophylaxis following craniotomy.
   Google Scholar